G Medical (ASX:GMV) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company brings forth the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity.
The Company specializes in innovative next generation mobile and e-health solutions and services using its suite of devices and software solutions with a view to driving multiple and recurring revenue streams, across numerous verticals and territories.
G Medical continuously strives to extend its regulatory approvals. Currently, Prizma is CE approved and FDA cleared. Recently the CE certification for Prizma was extended to include arrythmias detection. The G Medical Patch has a CE approval as a Holter devise.
G Medical has established presence in key territories to include US based Diagnostic Center that provides advanced remote patient monitoring services and a manufacturing production line in China.